Table 3.
Studied concerning associations between HLA-DRB1 and treatment response.
| Allele/Genotype | Treatment Response | f | Number of Patients (Male/Female) | Number of Patients Positive for Respective Variant | Number of Patients Anti-CCP-Positive at Diagnosis (%) | Additional Demographic Data | Reference |
|---|---|---|---|---|---|---|---|
| HLA-DRB1*0405 | Inadequate response to csDMARDs | 0.0003 | 124 (29/95) | 64 | 85.5 | Japanese population; mean disease duration 4.2 months; current/former smokers 19.3% | [143] |
| HLA-DRB1*0401/*0404 | favorable response to CsA | 0.016 | 54 (12/42) | 4 | unknown | Spanish population, Mean disease duration 12.1 years | [147] |
| HLA-DRB1*0401 | favorable primary response to TNF-α inhibitors | 0.007 | 1846 (432/1414) | 1188 | 83 | Data not shown | [123] |
| HLA-DRB1*03 | high risk of secondary failure to ADA | 0.006 | 634 | 37 | unknown | Data not shown | [152] |
| HLA-DRB1*01 | low risk of secondary failure to ADA | 0.012 | 365 | Data not shown | unknown | Data not shown | [152] |
| HLA-DRB1*07 | low risk of secondary unresponsiveness to ADA | 0.018 | 365 | Data not shown | unknown | Data not shown | [152] |
| HLA-DRB1 SE | higher efficacy response with ABA vs ADA at week 24 | Estimate of difference (95% CI) for DAS28 (CRP): 27.4 | 80 | 61 | unknown | Mean disease duration 5.5 months | [153] |
| HLA-DRB1 SE | favorable response to ABA at week 24 | <0.0001 | 72 (49/23) | 47 | 89 | Japanese population; mean disease duration 10.4 years | [154] |
csDMARDs = classical synthetic disease-modifying antirheumatic drugs; CsA = cyclosporine; ADA = adalimumab; ABA = abatacept.